A Case of Central Serous Chorioretinopathy Associated With Retinal Detachment Improved by Intravitreal Bevacizumab Injection.
10.3341/jkos.2010.51.10.1419
- Author:
Bum Ho SIN
1
;
Jae Keun JEOUNG
;
Sung Pyo PARK
Author Information
1. Department of Ophthalmology, Kang dong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. sungpyo@hananet.net
- Publication Type:Case Report
- Keywords:
Bevacizumab;
Chronic central serous chorioretinopathy (CSC)
- MeSH:
Adult;
Antibodies, Monoclonal, Humanized;
Central Serous Chorioretinopathy;
Eye;
Fluorescein;
Fluorescein Angiography;
Follow-Up Studies;
Humans;
Intravitreal Injections;
Male;
Retinal Detachment;
Retinaldehyde;
Tomography, Optical Coherence;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2010;51(10):1419-1422
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report a case of chronic central serous chorioretinopathy treated with an intravitreal injection of 2.5 mg of bevacizumab. CASE SUMMARY: A 38-year-old male complained of visual disturbance in the right eye. He had a history of central serous chorioretinopathy which improved without treatment. Since the patient did not feel any ocular discomfort, he did not visit our clinic for approximately 11 months. At the time of presentation, fundus examination revealed exudative retinal detachment involving the macular area. Additionally, fluorescein angiography revealed multiple early phase hyperfluorescent lesions. Neurosensory detachment around the macula and increased central macular thickness were also observed using optical coherence tomography. Under the diagnosis of chronic central serous chorioretinoapthy, the patient was treated with 2.5 mg of intravitreal bevacizumab. Visual acuity improved two months after treatment, with improvement in both neurosensory retinal detachment and fluorescein leakage. No changes were observed at the six-month follow-up.
